reports
- Jonathan Moreland
SBH SALLY BEAUTY HOLDINGS INC.
PRGO PERRIGO CO. PLC
NVCR NOVOCURE LTD.
KURA KURA ONCOLOGY INC.
GLP GLOBAL PARTNERS LP
FRPT FRESHPET INC
FLDM FLUIDIGM
FCN FTI CONSULTING INC.
CPRX CATALYST PHARMACEUTICALS
CE CELANESE CORPORATION
CDNA CAREDX INC
ASA ASA
AROW ARROW FINANCIAL CORP.
MDU MDU RESOURCES GROUP INC
ADC AGREE REALTY CORPORATION
CECE CECO ENVIRONMENTAL CORP.
ESP ESPEY MANUFACTURING & ELECTRONICS CORP.
BHB BAR HARBOR BANKSHARES
MFIN MEDALLION FINANCIAL CORP.
BSM BLACK STONE MINERALS LP
PLSE PULSE BIOSCIENCES
MLP MAUI LAND & PINEAPPLE CO. INC.
CELC CELCUITY
BRT BRT APARTMENTS
CCEL CRYO-CELL INTERNATIONAL
AEYE AUDIOEYE INC
DLHC DALEIGH HOLDINGS CORP
OPCH OPTION CARE HEALTH INC
SMMT SUMMIT THERAPEUTICS INC
CTO CONSOLIDATED-TOMOKA LAND CO
PFBX PEOPLES FINANCIAL CORP. (MISSISSIPPI)
NAUT NAUTILUS BIOTECHNOLOGY INC
ENOV ENOVIS CORPORATION
PFHC PROFRAC HLDG CORP
MLYS MINERALYS THERAPEUTICS INC
PROP PRAIRIE OPERATING CO.
DMA DESTRA MULTI ALTERNATIVE FUND
CAMP CAMP4 THERAPEUTICS CORPORATION
SFD SMITHFIELD FOODS INC.
AFCG AFC GAMMA
HYMC INC.
NIQ HYCROFT MINING HOLDING CORPORATION
NIQ GLOBAL INTELLIGENCE PLC
- Jonathan Moreland
FRPT FRESHPET INC
FLDM FLUIDIGM
FCN FTI CONSULTING INC.
ASA ASA
BHB BAR HARBOR BANKSHARES
MFIN MEDALLION FINANCIAL CORP.
BRT BRT APARTMENTS
SMMT SUMMIT THERAPEUTICS INC
CTO CONSOLIDATED-TOMOKA LAND CO
PFBX PEOPLES FINANCIAL CORP. (MISSISSIPPI)
ENOV ENOVIS CORPORATION
DMA DESTRA MULTI ALTERNATIVE FUND
CAMP CAMP4 THERAPEUTICS CORPORATION
- Jonathan Moreland
TPVG TRIPLEPOINT VENTURE GROWTH BDC CORP
SHEN SHENANDOAH TELECOMMUNICATIONS COMPANY
HTH HILLTOP HOLDINGS INC.
FLDM FLUIDIGM
COTY COTY INC. CLASS A
UPS UNITED PARCEL SERVICE INC. CLASS B
ASA ASA
MX MAGNACHIP SEMICONDUCTOR CORP.
ELTP ELITE PHARMACEUTICALS INC
GRX THE GABELLI HEALTHCARE & WELLNESSRX TRUST
MYO MYOMO
EBC EASTERN BANKSHARES INC
SUNS SUNRISE REALTY TRUST
GF THE NEW GERMANY FUND
AFCG INC.
SST AFC GAMMA
STSS INC.
SYSTEM1 INC
SHARPS TECHNOLOGY INC.
- Jonathan Moreland
PNFP PINNACLE FINANCIAL PARTNERS INC.
DLY LYONDELLBASELL INDUSTRIES NV
LLY ELI LILLY AND COMPANY
FLDM FLUIDIGM
AAOI APPLIED OPTOELECTRONICS INC.
SGMS SCIENTIFIC GAMES CORPORATION
VVV VALVOLINE INC.
CYRX CRYOPORT INC.
SMRT SMARTSPACE SOFTWARE
CLAR CLARUS CORPORATION
AVNS AVANOS MEDICAL INC.
ASAN ASANA
LUMN LUMEN TECHNOLOGIES INC.
PRCT PROCEPT BIOROBOTICS CORP
MSDL MORGAN STANLEY DIRECT LENDING
MDRR MEDALIST DIVERSIFIED REIT INC.
Standard BioTools Reports Second Quarter 2025 Financial Results
Standard BioTools Reports Second Quarter 2025 Financial Results SOUTH SAN FRANCISCO, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the second quarter ended June 30, 2025. Standard BioTools will no longer host its second quarter 2025 earnings call, previously scheduled for Monday, August 11 at 4:30 p.m. ET. Recent Highlights: Second quarter 2025 total combined company revenue of $42.0 million; Revenue from continuing operations of $21.8 millionAnnounced strategic sale of SomaLogi...
Standard BioTools and Precision Health Research, Singapore (PRECISE-SG...
Standard BioTools and Precision Health Research, Singapore (PRECISE-SG100K) Launch Proteomics Collaboration, Selecting SomaScan to Power Large-Scale Population Health Study PRECISE-SG100K will run 100,000 samples as part of an effort to transform precision health and medicine Reinforces SomaScan’s strategic position in the high-impact biobank segment and its increasing role in leading global health initiatives SOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that the Precision Health Research, Singapore (PRECISE-SG100K) ...
Standard BioTools Schedules Second Quarter Earnings Conference Call on...
Standard BioTools Schedules Second Quarter Earnings Conference Call on August 11, 2025 SOUTH SAN FRANCISCO, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will report second quarter 2025 financial results on Monday, August 11, 2025, after market close. The company will host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results and operational progress. Individuals can access the conference call by dialing: US domestic callers: (888) 346-3970Outside US callers: (412) 902-4297 Live audio of t...
Standard BioTools Enters Next Phase of Transformation with Strategic S...
Standard BioTools Enters Next Phase of Transformation with Strategic Sale of SomaLogic to Illumina Up To $425 Million In Total Proceeds Inclusive of Near-term Milestone Payments; $350 Million In Upfront Cash Retains Strategic Upside with Illumina Protein Prep Royalty Stream and Rights to Single SOMAmer Reagent Business Simplifies Operating Structure and Enables Achievement of Adjusted EBITDA Break-Even Cash & Cash Equivalents of At Least $550 Million Expected at Close to Fuel Inorganic Growth Strategy and Drive Long-Term Value Creation SOUTH SAN FRANCISCO, Calif., June 23, 2025 (...
Standard BioTools to Host Inaugural “Proteomics Roundtable” Webcast Se...
Standard BioTools to Host Inaugural “Proteomics Roundtable” Webcast Series Featuring top researchers and industry experts using high-throughput proteomics to drive breakthroughs in population health, translational research and clinical development SOUTH SAN FRANCISCO, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced the launch of its inaugural – a program of virtual events designed to spark conversation about the rapidly evolving field of proteomics. The series will spotlight thought leaders and industry experts discussing groundbreaking res...
Standard BioTools Reports First Quarter 2025 Financial Results
Standard BioTools Reports First Quarter 2025 Financial Results SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the first quarter ended March 31, 2025. Recent Highlights: First quarter 2025 revenue of $40.8 million45% reduction in operating loss and 29% improvement in adjusted EBITDA year-over-yearOperationalized $10 million more in annual run rate cost reductions, totaling $90 million since merger Strong balance sheet with $261 million in cash & cash equiva...
Standard BioTools Announces New Product Innovations in Plasma and Sing...
Standard BioTools Announces New Product Innovations in Plasma and Single-Cell Proteomics at AACR 2025 Expanded suite of consumables, instruments and services designed to empower researchers and accelerate next-generation drug development Ninety posters and presentations at AACR powered by the Standard BioTools proteomic portfolio to advance cancer research from target discovery to clinical development SOUTH SAN FRANCISCO, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced the launch of new and enhanced proteomic product offerings at the upcom...
Standard BioTools Schedules First Quarter Earnings Conference Call on ...
Standard BioTools Schedules First Quarter Earnings Conference Call on May 6, 2025 SOUTH SAN FRANCISCO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will report first quarter 2025 financial results on Tuesday, May 6, 2025, after market close. The company will host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results and operational progress. Individuals can access the conference call by dialing: US domestic callers: (888) 346-3970Outside US callers: (412) 902-4297 Live audio of the webca...
- Jonathan Moreland
VAC MARRIOTT VACATIONS WORLDWIDE CORPORATION
TDOC TELADOC HEALTH INC.
PBF PBF ENERGY INC. CLASS A
OMI OWENS & MINOR INC.
MTDR MATADOR RESOURCES COMPANY
LTRX LANTRONIX INC.
JCOM J2 GLOBAL INC.
FTAI FORTRESS TRANSPORTATION AND INFRASTRUCTURE INVESTORS LLC
FLDM FLUIDIGM
CDXS CODEXIS
FMC FMC CORPORATION
GTN GRAY TELEVISION INC.
PETS PETMED EXPRESS INC.
DMLP DORCHESTER MINERALS L.P.
LBSRD LIBERTY STAR URANIUM & METALS
GO GROCERY OUTLET HOLDING
PSN PARSONS
CAPR CAPRICOR THERAPEUTICS
VERX VERTEX
ORIC INC.
NOG ORIC PHARMACEUTICALS
PFBX NORTHERN OIL AND GAS
ALIT PEOPLES FINANCIAL CORP. (MISSISSIPPI)
TMCI ALIGHT
AVDX INC. / DELAWARE
FLYW TREACE MED CONCEPTS INC
MBC_w AVIDXCHANGE HLDGS INC
MRNA FLYWIRE CORP
CVI MASTERBRAND INC
GF MODERNA
INC.
CVR ENERGY
INC.
THE NEW GERMANY FUND
INC.
Standard BioTools to Participate in Upcoming Investor Conferences
Standard BioTools to Participate in Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that company management will participate in the following investor conferences: TD Cowen’s 45th Annual Healthcare Conference - March 3rd – 5th, 2025 Presenting on Monday, March 3, 2025, at 3:10 p.m. ET2025 Leerink Partners Global Healthcare Conference - March 9th – 12th, 2025Participating in investor meetings on March 12thKeyBanc’s 5th Annual Healthcare Forum – March 18th & 19th, 2025Presenting on Wednesday, ...
Standard BioTools Reports Fourth Quarter and Full Year 2024 Financial ...
Standard BioTools Reports Fourth Quarter and Full Year 2024 Financial Results SOUTH SAN FRANCISCO, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the fourth quarter and fiscal year ended December 31, 2024. Recent Highlights: Full Year 2024 pro forma combined revenue of $175.1 million17% Full Year reduction in pro forma operating loss and 33% year over year improvement in adjusted EBITDA Additional $10 million in operational cost reductions, now totaling $90 million in synergies o...
Standard BioTools Schedules Fourth Quarter and Full Year 2024 Earnings...
Standard BioTools Schedules Fourth Quarter and Full Year 2024 Earnings Conference Call on February 26, 2025 SOUTH SAN FRANCISCO, Calif., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will report fourth quarter and full year 2024 financial results on Wednesday, February 26, 2025, after market close. The company will host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results and operational progress. Individuals can access the conference call by dialing: US domestic callers: (888) 346-3970Outside US ...
Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2...
Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2024 Revenue Preliminary, unaudited revenue for the full year 2024 of approximately $174 million Presenting at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16th, 2024, at 9:45 a.m. PT. SOUTH SAN FRANCISCO, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (“Standard BioTools” or the “Company”) today announced preliminary and unaudited revenue results for the fourth quarter and full year 2024. Standard BioTools expects fourth quarter 2024 revenue of approxi...
Standard BioTools SomaScan Assay Powers Key Insights into Semaglutide ...
Standard BioTools SomaScan Assay Powers Key Insights into Semaglutide Treatment Published in Nature Medicine Novo Nordisk initiated study validates the power of proteomics to provide unique insights into mechanisms of action and expanded drug indications as well as the potential for shorter and smaller clinical trials SOUTH SAN FRANCISCO, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company”) announced today that its SomaScan™ Platform played a pivotal role in a study published in the current issue of titled “Proteomic changes upon treatment with...
Standard BioTools to Present at the 43rd Annual J.P. Morgan Healthcare...
Standard BioTools to Present at the 43rd Annual J.P. Morgan Healthcare Conference SOUTH SAN FRANCISCO, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced its President and Chief Executive Officer, Michael Egholm, PhD, will present at the upcoming 43rd Annual J.P. Morgan Healthcare Conference taking place on January 13th - 16th at the Westin St. Francis Hotel in San Francisco, CA. Dr. Egholm’s corporate presentation will be held on January 16th, 2024, at 9:45 a.m. PT. A live audio webcast will be available to investors and other interested ...
Standard BioTools Appoints Alex Kim as Chief Financial Officer
Standard BioTools Appoints Alex Kim as Chief Financial Officer SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq: LAB) today announced the appointment of Alex Kim as Chief Financial Officer, effective November 11, 2024. Kim, a co-founder and most recently Chief Operating Officer of Standard BioTools, brings nearly 30 years of financial and operations experience in the healthcare and life sciences industries to the role and will oversee Standard BioTools’ finance organization. Michael Egholm, President and ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.